| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
|
Br J Cancer
|
2006
|
2.57
|
|
2
|
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG).
|
Br J Cancer
|
2006
|
1.70
|
|
3
|
First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study.
|
Eur J Cancer
|
2001
|
1.11
|
|
4
|
Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
|
Ann Oncol
|
2006
|
1.09
|
|
5
|
Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
|
J Clin Oncol
|
2002
|
1.09
|
|
6
|
Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
|
Oncology
|
2005
|
1.06
|
|
7
|
Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.
|
Am J Clin Oncol
|
2000
|
1.02
|
|
8
|
Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial.
|
J Clin Oncol
|
1999
|
1.00
|
|
9
|
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.
|
Ann Oncol
|
2003
|
0.93
|
|
10
|
A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.
|
Br J Cancer
|
2012
|
0.91
|
|
11
|
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
|
Ann Oncol
|
2004
|
0.91
|
|
12
|
Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
|
Oncology
|
2002
|
0.89
|
|
13
|
An explosive course of squamous cell penile cancer in an AIDS patient.
|
Ann Oncol
|
2002
|
0.88
|
|
14
|
A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
|
Ann Oncol
|
2003
|
0.87
|
|
15
|
First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
|
Cancer
|
1998
|
0.86
|
|
16
|
Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial.
|
Eur J Cancer
|
1998
|
0.86
|
|
17
|
Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases.
|
Am J Clin Oncol
|
2000
|
0.86
|
|
18
|
Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial.
|
Ann Oncol
|
2004
|
0.85
|
|
19
|
Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial.
|
Cancer Chemother Pharmacol
|
1999
|
0.83
|
|
20
|
Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study.
|
Oncology
|
2001
|
0.82
|
|
21
|
Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.
|
Oncology
|
2004
|
0.82
|
|
22
|
Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.
|
Br J Cancer
|
2005
|
0.81
|
|
23
|
Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial.
|
Oncology
|
2003
|
0.81
|
|
24
|
First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study.
|
Ann Oncol
|
1998
|
0.80
|
|
25
|
Circulating serum levels of IL-20 in multiple myeloma patients: its significance in angiogenesis and disease activity.
|
Med Oncol
|
2015
|
0.80
|
|
26
|
Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group.
|
Ann Oncol
|
2006
|
0.80
|
|
27
|
Vinorelbine and cisplatin combination in pretreated patients with advanced non-small cell lung cancer pretreated with a taxane-based regimen: a multicenter phase II study.
|
Lung Cancer
|
2006
|
0.79
|
|
28
|
ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.
|
Lung Cancer
|
2003
|
0.79
|
|
29
|
Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer.
|
Am J Clin Oncol
|
1998
|
0.79
|
|
30
|
Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study.
|
Am J Clin Oncol
|
2002
|
0.78
|
|
31
|
Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report.
|
Semin Oncol
|
2000
|
0.78
|
|
32
|
Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study.
|
Lung Cancer
|
2003
|
0.78
|
|
33
|
Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
|
Lung Cancer
|
2006
|
0.78
|
|
34
|
Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen.
|
Semin Oncol
|
1997
|
0.77
|
|
35
|
A dose-escalation study of pegylated liposomal Doxorubicin and oxaliplatin in patients with advanced solid tumors.
|
Oncology
|
2007
|
0.77
|
|
36
|
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
|
Oncology
|
2004
|
0.77
|
|
37
|
Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study.
|
Ann Oncol
|
2001
|
0.77
|
|
38
|
Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study.
|
Lung Cancer
|
2001
|
0.77
|
|
39
|
Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results.
|
Semin Oncol
|
1997
|
0.77
|
|
40
|
Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: a multicenter phase II study of the Greek Cooperative Group for Lung Cancer.
|
Lung Cancer
|
1998
|
0.76
|
|
41
|
Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
|
Semin Oncol
|
1997
|
0.76
|
|
42
|
Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.
|
Oncology
|
2005
|
0.76
|
|
43
|
A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer.
|
Oncology
|
2001
|
0.76
|
|
44
|
A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours.
|
Br J Cancer
|
2007
|
0.75
|
|
45
|
Retracted
Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
|
Dig Dis
|
2007
|
0.75
|
|
46
|
Vinorelbine-based regimens as salvage treatment in patients with advanced non-small cell lung cancer: two parallel multicenter phase II trials.
|
Oncology
|
2001
|
0.75
|
|
47
|
Efficacy of phototherapy and/or exchange transfusions in neonatal jaundice.
|
Clin Pediatr (Phila)
|
1982
|
0.75
|
|
48
|
First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin.
|
Am J Clin Oncol
|
1999
|
0.75
|
|
49
|
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
|
Lung Cancer
|
2001
|
0.75
|
|
50
|
Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy.
|
Crit Rev Oncol Hematol
|
1999
|
0.75
|
|
51
|
Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
|
J Clin Oncol
|
1999
|
0.75
|
|
52
|
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
|
Oncology
|
2001
|
0.75
|
|
53
|
Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: A phase II trial.
|
J BUON
|
2007
|
0.75
|
|
54
|
A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors.
|
Am J Clin Oncol
|
2001
|
0.75
|
|
55
|
Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study.
|
Eur J Cancer
|
2000
|
0.75
|